Evidence map›Paper›PMID 33491649›Full record

ArticleeLife2021

TRIM37 prevents formation of centriolar protein assemblies by regulating Centrobin.

Fernando R Balestra, Andrés Domínguez-Calvo, Benita Wolf, Coralie Busso, Alizée Buff, Tessa Averink, Marita Lipsanen-Nyman, Pablo Huertas, Rosa M Ríos, Pierre Gönczy

Open access · goldAbstract read
In one paragraph

Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Mulibrey Nanism: Clinical Spectrum and Molecular Pathogenesis.International journal of molecular sciences · 2026
    Review
  5. Article
  6. Centriolar satellites regulatebioRxiv : the preprint server for biology · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. TRIMming centrosomal assemblies.Nature structural & molecular biology · 2025
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Fernando R BalestraDepartamento de Genética, Universidad de Sevilla, Sevilla, Spain.ORCID 0000-0003-2741-6068
Andrés Domínguez-CalvoDepartamento de Genética, Universidad de Sevilla, Sevilla, Spain.ORCID 0000-0002-3689-227X
Benita WolfSwiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland.ORCID 0000-0001-5673-4239
Coralie BussoSwiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland.
Alizée BuffSwiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland.
Tessa AverinkSwiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland.
Marita Lipsanen-NymanPediatric Research Center, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Pablo HuertasDepartamento de Genética, Universidad de Sevilla, Sevilla, Spain.ORCID 0000-0002-1756-4449
Rosa M RíosCentro Andaluz de Biología Molecular y Medicina Regenerativa-CABIMER, Universidad de Sevilla-CSIC-Universidad Pablo de Olavide, Sevilla, Spain.
Pierre GönczySwiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland.ORCID 0000-0002-6305-6883
École Polytechnique Fédérale de Lausanne · CHCentro Andaluz de Biología Molecular y Medicina Regenerativa · ESUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TRIM37 is an E3 ubiquitin ligase mutated in Mulibrey nanism, a disease with impaired organ growth and increased tumor formation. TRIM37 depletion from tissue culture cells results in supernumerary foci bearing the centriolar protein Centrin. Here, we characterize these centriolar protein assemblies (Cenpas) to uncover the mechanism of action of TRIM37. We find that an atypical de novo assembly pathway can generate Cenpas that act as microtubule-organizing centers (MTOCs), including in Mulibrey patient cells. Correlative light electron microscopy reveals that Cenpas are centriole-related or electron-dense structures with stripes. TRIM37 regulates the stability and solubility of Centrobin, which accumulates in elongated entities resembling the striped electron dense structures upon TRIM37 depletion. Furthermore, Cenpas formation upon TRIM37 depletion requires PLK4, as well as two parallel pathways relying respectively on Centrobin and PLK1. Overall, our work uncovers how TRIM37 prevents Cenpas formation, which would otherwise threaten genome integrity.

Indexed as

Cell Cycle ProteinsCell LineCentriolesHeLa CellsHumansMicrotubule-Organizing CenterMulibrey NanismTripartite Motif ProteinsUbiquitin-Protein LigasesCell Cycle ProteinsCNTROB protein, humanTRIM37 protein, humanTripartite Motif ProteinsUbiquitin-Protein Ligasescell biologyCentriolecentrobinCLEMhumanmicrotubule organizing centerMulibrey nanismTRIM37 E3 ligase

Identifiers

PMID33491649
PMCPMC7870141
OpenAlexW3125181524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.